Inaticabtagene Autoleucel

DB18356InvestigationalCell transplant therapies

Inaticabtagene Autoleucel: Overview.

Mechanism: Pharmacologically active on B-lymphocyte antigen CD19
Curator reviewed
Code names: CNCT-19

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Inaticabtagene Autoleucel, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.